Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 5/20 | 0.44 |
| ▸ | PTGIR | P43119 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 2/20 | 0.42 |
| ▸ | CNR2 | P34972 | 5/20 | 0.40 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.38 |
| ▸ | VCP | P55072 | 1/20 | 0.37 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1018532 | 0.88 | CNR1 (0.46) | MDM2CNR1CNR2PTGER1 | |
| SCHEMBL1017320 | 0.87 | KMO (0.43) | MDM2CNR1CNR2 | |
| SCHEMBL1018486 | 0.86 | PIN1 (0.40) | MDM2PIN1CYP3A4CYP2C19PDE4D | |
| SCHEMBL212661 | 0.83 | CNR1 (0.61) | CNR1CNR2 | |
| SCHEMBL212545 | 0.83 | CNR1 (0.53) | MDM2CNR1CNR2CYP1A2CYP3A4 | |
| SCHEMBL1017509 | 0.81 | NPC1 (0.43) | MDM2PTGER1PDE4D | |
| SCHEMBL4065346 | 0.80 | MAPT (0.43) | MDM2PIN1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL14856768 | 0.77 | CNR1 (0.56) | CNR1CNR2 | |
| SCHEMBL216677 | 0.77 | PIN1 (0.45) | MDM2PIN1CYP3A4CYP2C19PDE4D | |
| SCHEMBL14856810 | 0.77 | CNR1 (0.49) | MDM2PTGIRCNR1CNR2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130197226-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF LEFT VENTRICULAR DIASTOLIC DYSFUNCTION COMPRISING AN APOLIPOPROTEIN PEPTIDE/PHOSPHOLIPID COMPLEX | INSTITUT DE CARDIOLOGIE DE MONTREAL (CA) | 2013-08-01 | — | — | US | claimed |
| EP-2598158-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF LEFT VENTRICULAR DIASTOLIC DYSFUNCTION COMPRISING AN APOLIPOPROTEIN PEPTIDE/PHOSPHOLIPID COMPLEX | Institut de Cardiologie de Montréal (CA) | 2013-06-05 | — | — | EP | claimed |
| EP-2271632-B1 | 3-TRIFLUOROMETHYL-PYRAZINE-2-CARBOXYLIC ACID AMIDE DERIVATIVES AS HDL-CHOLESTEROL RAISING AGENTS | HOFFMANN LA ROCHE (CH) | 2013-04-17 | — | — | EP | claimed |
| WO-2012012870-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF LEFT VENTRICULAR DIASTOLIC DYSFUNCTION COMPRISING AN APOLIPOPROTEIN PEPTIDE/PHOSPHOLIPID COMPLEX | INSTITUT DE CARDIOLOGIE DE MONTREAL (CA) | 2012-02-02 | — | — | WO | claimed |
| WO-2009121741-A1 | 3-TRIFLUOROMETHYL-PYRAZINE-2-CARBOXYLIC ACID AMIDE DERIVATIVES AS HDL-CHOLESTEROL RAISING AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-10-08 | — | — | WO | claimed |
| US-20090247550-A1 | 3-TRIFLUOROMETHYL-PYRAZINE-2-CARBOXYLIC ACID AMIDE DERIVATIVES AS HDL-CHOLESTEROL RAISING AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-10-01 | — | — | US | claimed |
| US-20150374675-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF LEFT VENTRICULAR DIASTOLIC DYSFUNCTION COMPRISING AN APOLIPOPROTEIN PEPTIDE/PHOSPHOLIPID COMPLEX | INSTITUT DE CARDIOLOGIE DE MONTREAL (CA) | 2015-12-31 | — | — | US | disclosed |
| US-20140309426-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF LEFT VENTRICULAR DIASTOLIC DYSFUNCTION COMPRISING AN APOLIPOPROTEIN PEPTIDE/PHOSPHOLIPID COMPLEX | INSTITUT DE CARDIOLOGIE DE MONTRÉAL (CA) | 2014-10-16 | — | — | US | disclosed |
| US-20130197226-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF LEFT VENTRICULAR DIASTOLIC DYSFUNCTION COMPRISING AN APOLIPOPROTEIN PEPTIDE/PHOSPHOLIPID COMPLEX | INSTITUT DE CARDIOLOGIE DE MONTREAL (CA) | 2013-08-01 | — | — | US | disclosed |
| EP-2598158-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF LEFT VENTRICULAR DIASTOLIC DYSFUNCTION COMPRISING AN APOLIPOPROTEIN PEPTIDE/PHOSPHOLIPID COMPLEX | Institut de Cardiologie de Montréal (CA) | 2013-06-05 | — | — | EP | disclosed |
| EP-2271632-B1 | 3-TRIFLUOROMETHYL-PYRAZINE-2-CARBOXYLIC ACID AMIDE DERIVATIVES AS HDL-CHOLESTEROL RAISING AGENTS | HOFFMANN LA ROCHE (CH) | 2013-04-17 | — | — | EP | disclosed |
| WO-2012012870-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF LEFT VENTRICULAR DIASTOLIC DYSFUNCTION COMPRISING AN APOLIPOPROTEIN PEPTIDE/PHOSPHOLIPID COMPLEX | INSTITUT DE CARDIOLOGIE DE MONTREAL (CA) | 2012-02-02 | — | — | WO | disclosed |
| EP-2271632-A1 | 3-TRIFLUOROMETHYL-PYRAZINE-2-CARBOXYLIC ACID AMIDE DERIVATIVES AS HDL-CHOLESTEROL RAISING AGENTS | F. Hoffmann-La Roche AG (CH) | 2011-01-12 | — | — | EP | disclosed |
| WO-2009121741-A1 | 3-TRIFLUOROMETHYL-PYRAZINE-2-CARBOXYLIC ACID AMIDE DERIVATIVES AS HDL-CHOLESTEROL RAISING AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-10-08 | — | — | WO | disclosed |
| US-20090247550-A1 | 3-TRIFLUOROMETHYL-PYRAZINE-2-CARBOXYLIC ACID AMIDE DERIVATIVES AS HDL-CHOLESTEROL RAISING AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140309426-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF LEFT VENTRICULAR DIASTOLIC DYSFUNCTION COMPRISING AN APOLIPOPROTEIN PEPTIDE/PHOSPHOLIPID COMPLEX | APOB, FABP3, PLTP | MDM2 3674/4885PTGIR 256/4885CNR1 3767/4885 |
| US-20090247550-A1 | 3-TRIFLUOROMETHYL-PYRAZINE-2-CARBOXYLIC ACID AMIDE DERIVATIVES AS HDL-CHOLESTEROL RAISING AGENTS | CETP, APOB, PON1 | MDM2 4676/4885PTGIR 1372/4885CNR1 418/4885 |
| US-20150374675-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF LEFT VENTRICULAR DIASTOLIC DYSFUNCTION COMPRISING AN APOLIPOPROTEIN PEPTIDE/PHOSPHOLIPID COMPLEX | APOB, FABP3, PLTP | MDM2 3674/4885PTGIR 256/4885CNR1 3767/4885 |
| US-20130197226-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF LEFT VENTRICULAR DIASTOLIC DYSFUNCTION COMPRISING AN APOLIPOPROTEIN PEPTIDE/PHOSPHOLIPID COMPLEX | APOB, FABP3, PLTP | MDM2 3664/4885PTGIR 271/4885CNR1 3870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.